Table 1 Dysregulated ADAM10 in samples from AD patients
From: Therapeutic potential of ADAM10 modulation in Alzheimer’s disease: a review of the current evidence
Author | Year | Country | Specimen | Findings | References |
|---|---|---|---|---|---|
Aitana Sogorb-Esteve et al. | 2018 | Spain | CSF | proADAM10 levels remained unaltered decrease in ADAM10f and sADAM10 | [29] |
Izabela Pereira Vatanabe et al | 2021 | Brazil | Plasma and CSF | Increased plasma and CSF ADAM10 | [99] |
Maria Patrícia A. Oliveira Monteiro et al. | 2021 | Brazil | Plasma | Increased plasma ADAM10 | [100] |
Colciaghi et al. | 2004 | Italy | Platelet | Decreased Platelet ADAM10 | [101] |
Patricia Regina Manzine et al | 2015 | Brazil | Platelet | Decreased Platelet ADAM10 | [102] |
Anna Di Maio et al. | 2022 | Italy | Post-mortem brain tissue | Unchanged | [103] |
Lynn M. Bekris et al. | 2012 | USA | CSF | Decreased ADAM10 | [104] |
Wen-Hui Huang et al. | 2018 | China | Plasma | Decreased ADAM10 | [105] |
Minji Kim et al. | 2009 | USA | Plasma | Increased ADAM10 | [106] |